Study Summary
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
CD19 and CD22 targeted CAR-T cellsBIOLOGICAL
A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Chongqing University Cancer Hospital | Chongqing | Chongqing Municipality | China |